Axonyx Appoints Dr. Robert Burford as Vice President, Product Development.NEW YORK--(BUSINESS WIRE)--Dec. 6, 1999-- AXONYX Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: AXYX) announced today that Robert G. Burford, Ph.D., F.A.C.A. has been appointed by the Company as Vice President, Product Development. Dr. Burford will focus his efforts on preclinical and clinical development of AXONYX's cholinesterase inhibitor cholinesterase inhibitor n. A drug, such as neostigmine, that restores myoneural function by inhibiting the biodegradation of acetylcholine. Also called acetylcholinesterase inhibitor. drug candidates, including Phenserine, its lead compound for Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Last month AXONYX announced that the Company cleared all regulatory requirements Regulatory requirements are part of the process of drug discovery and drug development. Regulatory requirements describe what is necessary for a new drug to be approved for marketing in any particular country. necessary to commence its Phase I U.S. human trials with Phenserine. AXONYX anticipates beginning the Phenserine clinical study before the end of the year. These drugs are being developed for the treatment of patients suffering from Alzheimer's Disease and other forms of memory impairment. "The addition of Dr. Burford, a proven pharmaceutical industry executive, will assist the Company in moving its compounds into the clinic for human testing," said Dr. Marvin S. Hausman, the Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Development of Phenserine, a third generation acetylcholinesterase inhibitor acetylcholinesterase inhibitor n. See cholinesterase inhibitor. with unique beta amyloid amyloid /am·y·loid/ (am´i-loid) 1. starchlike; amylaceous. 2. the pathologic, extracellular, waxy, amorphous substance deposited in amyloidosis, being composed of fibrils in bundles or in a meshwork of polypeptide inhibitory properties, holds a great deal of promise for both the Company and Alzheimer's patients alike. This dual activity of Phenserine opens up a potential new treatment avenue for Alzheimer's Disease patients: slowing the disease process as well as memory improvements," continued Dr. Hausman. Dr. Burford brings 34 years of pharmaceutical research experience to the Company, particularly in clinical development of new drugs. For 17 years he was Director, Clinical Research and then Director, Scientific Affairs for Searle Pharmaceuticals, following which for 6 years he was Director, Scientific Affairs for Biovail Corporation International. Throughout his career he has been intimately involved in planning and managing clinical studies of new chemical entities in support of regulatory submissions in both domestic and foreign markets. For the past ten years Dr. Burford has been president of American Clinical Research Consultants where he has provided preclinical and clinical consulting services Noun 1. consulting service - service provided by a professional advisor (e.g., a lawyer or doctor or CPA etc.) service - work done by one person or group that benefits another; "budget separately for goods and services" to a wide variety of pharmaceutical industry clients. A pharmacologist/toxicologist by training, Dr. Burford brings to AXONYX strong project management skills and experience. AXONYX Inc. is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders. This press release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. or predictions. These statements represent our judgment as of this date and are subject to risks and uncertainties that could materially affect the Company. AXONYX undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion